Capital Research Global Investors Discloses 10.77M Share Stake in BioMarin

TL;DR

**Big fund Capital Research Global Investors just revealed a huge 10.77 million share position in BioMarin.**

AI Summary

Capital Research Global Investors, a major investment firm, reported owning 10,774,641 shares of BioMarin Pharmaceutical Inc. common stock as of December 29, 2023. This represents a significant stake, giving them sole voting power over 10,752,504 shares and sole dispositive power over 10,774,641 shares. This matters to investors because a large institutional holding by a reputable firm like Capital Research Global Investors can signal confidence in BioMarin's future prospects, potentially attracting more investors and influencing stock stability.

Why It Matters

This filing indicates a major institutional investor, Capital Research Global Investors, has a substantial stake in BioMarin, which can be seen as a vote of confidence in the company's value and future.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, generally viewed as a positive signal rather than a risk.

Analyst Insight

A smart investor would view this significant institutional holding as a positive indicator, potentially prompting further research into BioMarin's fundamentals and considering it as a stable long-term investment.

Key Numbers

• 10,774,641 — Aggregate Amount Beneficially Owned (Total shares of BioMarin Pharmaceutical Inc. owned by Capital Research Global Investors)
• 10,752,504 — Sole Voting Power (Number of shares Capital Research Global Investors has sole voting control over)
• 10,774,641 — Sole Dispositive Power (Number of shares Capital Research Global Investors has sole power to sell or dispose of)
• 09061G101 — CUSIP Number (Unique identifier for BioMarin Pharmaceutical Inc. common stock)

Key Players & Entities

• Capital Research Global Investors (company) — the reporting person and institutional investor
• BioMarin Pharmaceutical Inc. (company) — the subject company whose shares are being reported
• Delaware (company) — place of organization for Capital Research Global Investors
• December 29, 2023 (date) — date of event requiring the filing

Forward-Looking Statements

• BioMarin Pharmaceutical Inc. stock may experience increased stability due to significant institutional backing. (BioMarin Pharmaceutical Inc.) — medium confidence, target: next 6-12 months

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G) — 16KB
• 0001422848-24-000031.txt ( ) — 18KB

From the Filing

SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _ ) * BioMarin Pharmaceutical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061G101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 09061G101 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research Global Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 10,752,504 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 10,774,641 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,774,641 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.7% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer BioMarin Pharmaceutical Inc. (b) Address of Issuer's Principal Executive Offices 770 Lindaro Street, San Rafael, CA 94901 Item 2. (a) Name of Person Filing Capital Research Global Investors (b) Address of Principal Business Office or, if None, Residence 333 South Hope Street, 55th Fl, Los Angeles, CA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 09061G101 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J). Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 10,774,641 ** (b) Percent of Class: 5.7% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 10,752,504 (ii) shared power to vote or to direct the vote 0 (iii) sole power to dispose or to direct the disposition of 10,774,641 (iv) shared power to dispose or to direct the disposition of 0 **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 10,774,641 shares or 5.7% of the 188,368,171 shares believed to be outstanding. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be th

View Full Filing

View this SC 13G filing on SEC EDGAR